Pharmacological treatment of severely depressed patients: A meta- analysis comparing efficacy of mirtazapine and amitriptyline

European Neuropsychopharmacology

Volumn 7, Issue 2, 1997, Pages 115-124

  Kasper, S ^a   Zivkov, M ^b   Roes, K C B ^c   Pols, A G ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b Medical Services Department   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Biometrics Department   (Netherlands)

Author keywords

Amitriptyline; Antidepressants; Major depression; Mirtazapine (Org 3770); Severe depression

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; MIRTAZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED;

EID: 0030988526     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00394-X     Document Type: Article

References (52)

1. American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders, 3 ed. American Psychiatric Association, Washington DC.
2. Anderson, I.M. and Tomenson, B.M. (1994) The efficacy of selective scrotonin re-uptake inhibitors in depression: a meta-analysis of studies against tryciclic antidepressants. J. Psychopharmacol. 8, 238-249.
3. Bakish, D. (1991) Fluoxetine potentiation by buspirone: Three case histories. Can. J. Psychiatry. 31, 749-750.
4. Bech, P., Gram, L.F., Dein, O., Jacobsen, O., Vitger, J. and Bolwig T.G. (1975) Quantitative rating of depressive states. Acta Psychiat. Scand. 51, 161-170.
5. Bremner, J.D. (1995) A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J. Clin. Psychiatry 56, 519-526.
6. Bulpitt, C.J. (1988) Medical statistics: meta-analysis. Lancet 2, 93-94.
7. Burke, M.J. and Preskorn, S.H. (1995) Short-term treatment with standard antidepressants. In: Psychopharmacology: The Fourth Generation of Progress. Bloom, F.E. and Cooper, D.J. (Eds.), Raven Press, Ltd., New York, pp. 1053-1065.
8. Burton, S.W. (1993) Symptoms as predictors of response in depression. J. Psychopharmacol. 7(Suppl), 135-138.
9. Claghorn, J.L. and Lessem, M.D. (1995) A double-blind, placebo-controlled study of Org 3770 in depressed outpatients. J. Affect. Disord. 34, 165-171.
10. Cleary, P. and Guy, W (1977) Factor analysis of the Hamilton Depression Scale. Drugs. Exptl. Clin. Res. 1, 115-120.
11. Danish University Antidepressant Group (1986) Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 90, 131-138.
12. Danish University Antidepressant Group (1990) Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. J. Affect. Disord. 18, 289-299.
13. J. Clin. Psychiatry, Data on file, NV. Organon, Oss, The Netherlands.
14. 1A-mediated serotonergic neurotransmission. CNS Drugs 4(suppl 1), 29-38.
15. de Boer, Th., Maura, G., Raiteri, M., De Vos, C.J., Wieringa, J. and Pinder, R.M. (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 27, 399-408.
16. 2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol. 253, R5-6.
17. de Montigny, C., Haddjeri, N., Mongeau, R. and Blier, P. (1995) The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs 4(suppl 1), 13-17.
18. Dubovsky, S.L. and Thomas, M. (1995) Serotonergic mechanisms and current and future psychiatric practice. JOURNAL??? 56(Suppl 2), 38-48.
19. Feigner, J.P., Cohn, J.B., Fabre, Jr. L.F., Fieve, R.R., Mendels, J., Shrivastava, R.K. and Dunbar, G.C. (1993) A study comparing paroxetine, placebo and imipramine in depressed patients. J. Affect. Disord. 28, 71-79.
20. Goodwin, F.K. (1994) Psychiatry. JAMA. 271, 1707-1708.
21. Gram, L. (1995) Fluoxetine. N. Engl. J. Med. 332, 960-961.
22. Gram, L.F., Reisby, N. and Ibsen, I. (1976) Plasma levels and antidepressive effect of imipramine. Clin. Pharmacol. Ther. 19, 318-324.
23. Hamilton, M. (1960) A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62.
24. Høyberg, O.J., Maragakis, B., Mullin, J., Norum, D., Stordall, E., Ekhdal, P., Ose, E., Moksnes, K.M. and Sennef, C. (1996) A double-blind, amitriptyline-controlled, multicentre study of Org 3770 in the treatment of elderly depressed patients. Acta Psychiat. Scand. 93, 184-190.
25. Jacobsen, F.M. (1991) Possible augmentation of antidepressant response by buspirone. J. Clin. Psychiatry 52, 217-220.
26. Joffe, R.T. and Schuller, D.R. (1993) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry 54, 269-271.
27. Kasper, S. (1993) Is severe depression a different fitness? The pharmacological evidence. Eur. Neuropsychopharmacol. 3, 213-217.
28. Kasper, S. (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int. Clin. Psychopharmacology 10(suppl 4), 25-37.
29. Kasper, S., Fuger, J. and Möller, H.J. (1992) Comparative efficacy of antidepressants. Drugs 43(suppl 2), 11-23.
30. Kasper, S., Möller, H-J., Montgomery, S.A. and Zondag, E. (1995) Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int. Clin. Psychopharmacol. 9(suppl 4), 3-12.
31. Katz, M., Koslow, M. and Maas, J. (1987) The timing, specificity and prediction of tricyclic drug effects in depression. Psychol. Med. 17, 297-309.
32. Klieser, E., Lehman, E. and Heinrich, K. (1995) Fluoxetine in patients with major depressive disorder - a responder analysis. Pharmacopsychiatry 28, 14-19.
33. Koch, G.G. and Carr, J. (1990) Categorical data analysis. In: Berry, D.A. (Ed.), Statistical Methodology in the Pharmaceutical Sciences. Marcel Decker, New York, pp. 389-473.
34. Lipsitz, J. and Williams, J.B.W. (1994) Assessment of severe depressive disorders. In: Grunhaus, L. and Greden J.F. (Eds.), Severe Depressive Disorders. American Psychiatric Press, Washington, DC., pp. 1-22.
35. Marttila, M., Jääkeläinen, J., Järvi, R., Romanov, M., Sorri, P., Ahlfors, U. and Zivkov, M. (1995) A double-blind study comparing the efficacy and tolerability of Org 3770 and doxepin patients with major depression. Eur. Nuropsychopharmacol. 15, 441-446.
36. Montgomery, S.A. (1992) The advantages of paroxetine in different subgroups of depression. Int. Clin. Psychopharmacol. 6(Suppl 4), 91-100.
37. Montgomery, S.A. (1994) Clinically relevant effect sizes in depression. Eur. Neuropsychopharmacol. 4, 283-284.
38. Mullin, J., Lodge, A., Bennie, E., McCreadie, R., Bhatt, G.S. and Fenton G. (1996) A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J. Psychopharmacol. 10, 235-240
39. Ottevanger, E.A. (1994) The efficacy of fluvoxamine in patients with severe depression. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 18, 731-740.
40. Pande, A.C. and Sayler, M.E. (1993) Severity of depression and response to fluoxetine. Int. Clin. Psychopharmacol. 8, 243-245.
41. Paykel, E., Hollyman, J. and Freeling, P. (1988) Predictor for therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J. Affect. Disord. 245, 83-95.
42. Peto, R. (1987) Why do we need systematic overviews of randomized trials? Statis. Med. 6, 233-240.
43. Preskorn, S.H. (1995) Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? Int. Rev. Psychiatry 7, 17-28.
44. Richou, H., Ruimy, P., Charbaut, J., Delisle, J.P., Brunner, H., Patris, M. and Zivkov, M. (1995) A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol. 10, 263-271.
45. Schmid, J.E., Koch, G. and LaVange, L.M. (1991) An overview of statistical issues and methods of meta-analysis. J. Biopharmaceut. Stat. 1, 103-120.
46. Schulz, K.F., Chalmers, I., Hayes, R.J. and Altman, D.G. (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimated treatment effects in controlled trials. JAMA. 273, 408-412.
47. Smith, W.T., Glaudin, V., Panagides, J. and Gilvary, E. (1990) Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacol. Bull. 26, 191-196.
48. Van Moffaert, M., de Wilde, J., Vereecken, A., Dierick, M., Evrard, J.L., Wilmotte, J. and Mendlewicz, J. (1995) Miirtazapine is more effective than trazodone. A controlled study in hospitalised patients with major depression. Int. Clin. Psychopharmacol. 10, 3-9.
49. Vestergaard, P., Gram, L.F., Kragh-Sørensen, P., Bech, P., Reisby, N., Bolwig, T.G. and the Danish University Antidepressant Group(1993) Therapeutic potentials of recently introduced antidepressants. Psychopharmacol. Ser. 10, 190-198.
50. Whitehead, A. and Whitehead, J. (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Statist. Med. 10, 1665-1677.
51. Zivkov, M. and de Jongh, G.D. (1995) Org 3770 vs amitriptyline: a 6-week, randomised, double-blind multicentre trial in hospitalised depressed patients, Hum. Psychopharmacol. 10, 173-180.
52. Zivkov, M., Roes, K.C.B. and Pols, A.G. (1995) Efficacy of Org 3770 and amitriptyline in patients with major depressive disorder: a meta-analysis. Hum. Psychopharmacol. 10(suppl 2), S135-S145.